# Aged garlic extract 2.4-7.2 g/day × Reduction of ex vivo platelet aggregation Verdict 3066 · Evidence Check Stored-material review date: 2026-10-05 Original evidence review date: 2026-09-08 Review-criteria version: 1.2 Public page/material preparation date: 2026-10-26 Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect. ## Assessment scope - Population: The broad scope mainly concerns healthy adults. Direct material linking the small sample of healthy men in the 1995 report to the actual arachidonic acid population or arm-specific analysis counts remains unverified. - Ingredient, formulation and route: The selected conditions concern oral Allium sativum clove aged-extract AGE capsules. The direct arachidonic acid product, batch, manufacture/aging and SAC/ingredients remain unverified. Other garlic preparations are not substituted. - Dose: The broad AGE doses of 2.4, 4.8 and 7.2 g/day belong to a 34-person dose trial on other agonists. Actual arachidonic acid route, dose and intake/adherence remain unverified. The link between nominal doses and the ADP result cell is also unverified. - Comparator: The selected question is AGE versus placebo. A direct placebo comparison matching the actual arachidonic acid product, population, measure and time, its analysis population and between-arm contrast remain unverified. - Measured outcome: The question concerns a gap in direct AGE results for arachidonic acid-induced platelet aggregation. The endpoint name is retained in the Korean/English crux, but direct reports, numerical results, CI and denominators remain unverified in the current 3 evidence entries and 3 citations. - Duration: Exact arachidonic acid intake duration, blood-draw/testing times, discontinuation/washout and post-discontinuation results remain unverified. The broad short-term, trial-varying description is not converted into a specific duration. - Questions outside this scope: Original C, 46 points, Warning and B/S/R0/I1/EX/B2/CX are historical records of the broad parent verdict. No separate arachidonic acid grade or direct effect is created.; S01’s 34 people are the overall context of another agonist/dose trial. They are neither transferred as arm-specific arachidonic acid analysis counts or unique-replication participants nor added together.; The 1995 report concerns ADP, PAF and collagen; arachidonic acid is not named in its retained endpoint. AGE identity is also unverified. No significant oral effect does not establish an arachidonic acid effect of 0, equivalence or direct AGE refutation.; The review’s 12 RCTs, 595 people and 6 positive trials are overall summary counts. Directly eligible AGE/arachidonic acid trials, results, denominators, overlap and unique replications remain unverified.; Clinical thrombosis prevention, aspirin replacement, optimal dose and long-term persistence are separate extensions beyond this narrow gap question. Bleeding warnings are retained; unverified harms are not converted into safety or absence of events. ## Checklist items ### N01 · Is the broad parent text distinguished from the arachidonic acid result-gap question? Verification status: Met Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The original effect statement is reduction of ex vivo platelet aggregation. This table asks about the gap in direct AGE results for the arachidonic acid response separately named in the crux. This subquestion is not an index in the original subclaim array. - Why unverified: The defined boundary is linked to the original text; naming a response creates neither new efficacy evidence nor a paper. - Reason for missing information: The identity of the question is verified. This does not establish that the AGE effect on this response is known. - Required materials and conditions: The original broad claim, endpoint name in the crux, derived comparison and change history. - Materials to obtain first: The original broad claim, endpoint name in the crux, derived comparison and change history. - Further research: If the question changes, compare the explicitly named original endpoint with the new scope. - Conditions for verification: Keep the original effect statement and empty subclaim list unchanged; separately fix the question of direct AGE evidence for arachidonic acid-induced responses. - Why this condition is needed: Distinguish a named endpoint's evidence gap from the existing broad parent verdict. - Application exceptions: This subquestion is not an original subclaim and creates no separate clinical grade. - Remaining uncertainty: The identity of the question is verified. This does not establish that the AGE effect on this response is known. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N02 · Is a direct AGE arachidonic acid report and comparison verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Arachidonic acid is explicitly named as an endpoint in the Korean/English crux. The current 3 evidence entries and 3 citations do not verify a direct result or report for it. All 3 existing reports are retained; no new S04 or paper is created. - Why unverified: An endpoint name is not evidence that a direct trial/paper or an AGE-placebo result exists. - Reason for missing information: The identity of a direct AGE report/comparison for this response and its actual result remain unverified. - Required materials and conditions: Original reports, methods, results and citations linking AGE, arachidonic acid and an actual comparator. - Materials to obtain first: Original reports, methods, results and citations linking AGE, arachidonic acid and an actual comparator. - Further research: First compare this endpoint against the complete plans/results of the current 3 reports; record the presence or absence of direct material within a stated scope. - Conditions for verification: Identify an actual report establishing formulation, population, arachidonic acid endpoint, placebo and timing together. - Why this condition is needed: Do not fill an empty result with an invented report. - Application exceptions: Do not turn a gap in the current summary into worldwide absence of studies, existence of a paper or a null effect. - Remaining uncertainty: The identity of a direct AGE report/comparison for this response and its actual result remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N03 · Are the selected AGE identity and actual arachidonic acid trial-product specifications verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The broad claim conditions describe Allium sativum clove aged-extract AGE capsules and unverified trial-specific SAC specifications. The direct arachidonic acid product, batch and SAC/ingredients are currently unverified. - Why unverified: A broad product name exists, but direct material for comparing the selected-response trial product's identity is unavailable. - Reason for missing information: Actual product, specification and matching to AGE for the arachidonic acid response are unavailable. - Required materials and conditions: Product name, manufacture/aging, batch, SAC/ingredients and comparison specifications in methods for the selected response. - Materials to obtain first: Product name, manufacture/aging, batch, SAC/ingredients and comparison specifications in methods for the selected response. - Further research: Verify the product's molecular identity, manufacture and specifications before comparing result eligibility. - Conditions for verification: Distinguish the broad AGE capsule identity from the product/batch, SAC, manufacture/aging and ingredients used for the selected response. - Why this condition is needed: Do not transfer selected-response results to another garlic formulation or isolated ingredient. - Application exceptions: Do not assume that the 1995 garlic preparation is AGE or an arachidonic acid trial product. - Remaining uncertainty: Actual product, specification and matching to AGE for the arachidonic acid response are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N04 · Are actual route, dose and intake linked to the arachidonic acid result verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The broad original text describes oral AGE at 2.4, 4.8 and 7.2 g/day. These doses belong to the context of a 34-person report on other agonists; actual route, dose and intake for arachidonic acid remain unverified. - Why unverified: Actual exposure data linked to the selected-response result are unavailable. - Reason for missing information: Route, dose, adherence and changes/discontinuation for people measured for arachidonic acid remain unverified. - Required materials and conditions: Product/administration records, intake/adherence, changes/discontinuation and a measurement linkage table for the selected response. - Materials to obtain first: Product/administration records, intake/adherence, changes/discontinuation and a measurement linkage table for the selected response. - Further research: Link exposure records to aggregation-test participants; separate broad nominal doses from actual amounts for the selected response. - Conditions for verification: Directly verify the route, product/active amount, frequency and adherence of exposure in which this response was measured. - Why this condition is needed: The stated amount for another result does not establish exposure for the selected response. - Application exceptions: Do not substitute the nominal 7.2 g/day in the parent dose list or the weak ADP threshold signal at the highest dose for actual arachidonic acid dose/effect. The link between nominal doses and the ADP result cell also remains unverified. - Remaining uncertainty: Route, dose, adherence and changes/discontinuation for people measured for arachidonic acid remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N05 · Are the actual population, eligibility and baseline status for the arachidonic acid response verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The broad population mainly concerns healthy adults; the 1995 candidate is a small sample of healthy men. Direct material linking these to the actual arachidonic acid population or arm-specific analysis n is unavailable. - Why unverified: Direct population/eligibility information for a reported selected response is unverified. - Reason for missing information: Population/eligibility, baseline, co-use and representativeness data for arachidonic acid measurements are unavailable. - Required materials and conditions: Population/eligibility, baseline tables, medication/disease exclusions and analysis population for the selected response. - Materials to obtain first: Population/eligibility, baseline tables, medication/disease exclusions and analysis population for the selected response. - Further research: Link actual participants to aggregation-test data; do not expand applicability using a broad population label. - Conditions for verification: Verify population, inclusion/exclusion, baseline function, disease/co-medication and actual analysis population in the selected-response report. - Why this condition is needed: Do not repurpose a population from another result as the direct selected-response population. - Application exceptions: Do not treat healthy adults, 34 people or a small male sample as an established selected-response population. - Remaining uncertainty: Population/eligibility, baseline, co-use and representativeness data for arachidonic acid measurements are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02 ### N06 · Are arachidonic acid exposure duration and testing times verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The broad duration is short-term and varies by trial; exact administration duration, blood-draw/testing times and post-discontinuation results for arachidonic acid are currently unverified. - Why unverified: A direct schedule supporting the selected-response timing conditions is unavailable. - Reason for missing information: Exposure duration and blood-draw/testing/follow-up schedules for arachidonic acid results remain unverified. - Required materials and conditions: Administration/discontinuation, washout, blood-draw/testing schedules and result times for the selected response. - Materials to obtain first: Administration/discontinuation, washout, blood-draw/testing schedules and result times for the selected response. - Further research: Compare planned and actual testing dates; distinguish responses at different times. - Conditions for verification: Link administration, discontinuation/washout, blood draw and testing times under the same comparison conditions. - Why this condition is needed: Do not convert nominal short-term wording into a specific selected-response assessment time. - Application exceptions: Do not automatically inherit another trial's duration or persistence of effect. - Remaining uncertainty: Exposure duration and blood-draw/testing/follow-up schedules for arachidonic acid results remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N07 · Are the named arachidonic acid endpoint and exact measure verified? Verification status: Partly verified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The Korean/English crux distinguishes arachidonic acid from other agonists. Maximum aggregation/threshold, concentration, test method, unit and direction for this response remain unverified in retained evidence. - Why unverified: The endpoint name is verified, while actual measurement conditions remain unresolved. - Reason for missing information: Measure, concentration, unit and collection/assessment procedures for arachidonic acid aggregation testing are unavailable. - Required materials and conditions: Aggregation-test methods, specimen/equipment, agonist concentration, measure/unit and assessment procedures for the selected response. - Materials to obtain first: Aggregation-test methods, specimen/equipment, agonist concentration, measure/unit and assessment procedures for the selected response. - Further research: Directly link methods to result measures; distinguish ADP/other-agonist material. - Conditions for verification: Retain the endpoint name in the crux; verify maximum aggregation/threshold, agonist concentration, specimen, test method, unit and direction. - Why this condition is needed: Existence of a name and actual measurement are different facts. - Application exceptions: Do not select broad maximum aggregation or threshold as the exact measure for this response. - Remaining uncertainty: Measure, concentration, unit and collection/assessment procedures for arachidonic acid aggregation testing are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N08 · Are allocation, blinding and co-use for a direct arachidonic acid comparison verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: S01 is a randomized double-blind placebo dose trial; S02 is a double-blind placebo trial. Neither design label is linked to direct arachidonic acid results; selected-response allocation, co-use and blinding remain unverified. - Why unverified: A design for another endpoint is not verified as a direct selected-response design. - Reason for missing information: Direct comparator, allocation/concealment, co-use, baseline and assessment-procedure data for the selected response are unavailable. - Required materials and conditions: Original methods, comparator composition, allocation/concealment, co-use/adherence and assessment blinding for the selected response. - Materials to obtain first: Original methods, comparator composition, allocation/concealment, co-use/adherence and assessment blinding for the selected response. - Further research: Identify a direct selected-response report before comparing its methods with actual conduct. - Conditions for verification: Verify actual comparator, allocation/concealment, baseline, co-use/adherence and assessment procedures for the selected-response result. - Why this condition is needed: An RCT label alone does not establish that a comparison for another response exists. - Application exceptions: Do not turn an unverified selected-response study into an established parallel/crossover design or randomization failure. - Remaining uncertainty: Direct comparator, allocation/concealment, co-use, baseline and assessment-procedure data for the selected response are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02 ### N09 · Are the actual direction and effect value for arachidonic acid verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The current 3 evidence entries and 3 citations do not verify actual arachidonic acid effect values, direction or analysis results. Reductions for other agonists or the 1995 nonsignificant wording are not substituted. - Why unverified: Without a direct original selected-response result, observations remain unrecorded. - Reason for missing information: An original location for direct arachidonic acid direction, effect, timing and analysis is unavailable. - Required materials and conditions: Selected-response result tables, original arm-level observations, effect direction/unit and contrast definition. - Materials to obtain first: Selected-response result tables, original arm-level observations, effect direction/unit and contrast definition. - Further research: Extract the selected-response result directly from the original report; attribute actual values, comparison and time. - Conditions for verification: Link original results, between-arm/within-arm contrasts, unit, timing and analysis for this response to an actual report. - Why this condition is needed: Do not invent positive, no-difference or unfavorable results. - Application exceptions: Do not turn an unverified result into an effect of 0, a null effect or an opposing result. - Remaining uncertainty: An original location for direct arachidonic acid direction, effect, timing and analysis is unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N10 · Are allocation, analysis and missing-data n for arachidonic acid verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: S01's 34 people, S02's small sample and S03's 12 RCTs/595 people are their respective report contexts. Arm-specific allocated, measured and analyzed n and missing data for arachidonic acid remain unverified. - Why unverified: Evidence linking existing report totals to actual selected-response denominators is unavailable. - Reason for missing information: Analyzed n, completion, missing data and attrition reasons/handling for the selected response are unavailable. - Required materials and conditions: Arm-level flow, measured/analyzed n and reasons/handling of missing data for each selected-response aggregation test. - Materials to obtain first: Arm-level flow, measured/analyzed n and reasons/handling of missing data for each selected-response aggregation test. - Further research: Link analysis populations to reports, participants and aggregation tests; do not substitute overall totals across them. - Conditions for verification: Verify arm-specific allocated/measured/completed/analyzed n, attrition reasons and missing-data handling for the selected response. - Why this condition is needed: Totals for other endpoints are not selected-response denominators. - Application exceptions: Do not add 34 and 595 or calculate a new unique participant count. - Remaining uncertainty: Analyzed n, completion, missing data and attrition reasons/handling for the selected response are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N11 · Are selected-response analysis, variance, CI and important differences verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Arachidonic acid effect estimates, models, SD/SE, CI, significance level and important-difference criteria remain unverified. The broad original EX/CX axes are not an individual selected-response analysis. - Why unverified: Without selected-response effects and variance data, an interpretable interval cannot be verified. - Reason for missing information: Original estimates, variance, intervals and importance criteria are unavailable; they are not filled by new calculations. - Required materials and conditions: Selected-response analysis plans, estimates, variance/CI and support for important-difference criteria. - Materials to obtain first: Selected-response analysis plans, estimates, variance/CI and support for important-difference criteria. - Further research: When actual estimates and intervals are obtained, compare them with planned analyses and important-difference criteria. - Conditions for verification: Verify models, assignment/adherence effects, SD/SE, CI and important-difference criteria for arachidonic acid estimates. - Why this condition is needed: Do not judge precision or sufficiency from broad axes or sample sizes. - Application exceptions: Do not invent CI, P, an effect of 0 or a minimum participant threshold. - Remaining uncertainty: Original estimates, variance, intervals and importance criteria are unavailable; they are not filled by new calculations. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N12 · Are planned versus actual arachidonic acid measurement or omission verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Registration is marked unconfirmed in the original 3 evidence entries. Naming arachidonic acid in the crux does not verify that it was actually planned, measured or omitted. Comparison of plans, registration and results remains unverified. - Why unverified: An endpoint name proves neither planning, conduct nor omission; actual comparison material is unavailable. - Reason for missing information: Selected-response prespecification, measurement conduct, reasons for nonreporting/changes and multiplicity rules are unavailable. - Required materials and conditions: Original registration/protocols, complete agonist plans, actual aggregation tests/results and change history. - Materials to obtain first: Original registration/protocols, complete agonist plans, actual aggregation tests/results and change history. - Further research: Compare initial plans with actual specimens/results; distinguish unplanned, unmeasured, summary-omitted and unreported results. - Conditions for verification: Verify selected-response plans, registration, dose/concentration/timing, analysis, actual publication reporting and reasons for changes. - Why this condition is needed: Do not turn a summary gap into established selective reporting across the entire paper. - Application exceptions: Do not treat unobtained registration as nonregistration or a crux name as preregistration. - Remaining uncertainty: Selected-response prespecification, measurement conduct, reasons for nonreporting/changes and multiplicity rules are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N13 · Are other-agonist signals from the 34-person AGE trial retained unchanged? Verification status: Met Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Known results of the 34-person AGE dose trial are partial collagen/epinephrine reductions and a weak ADP threshold signal at the highest dose. They are not promoted to arachidonic acid results. - Why unverified: Actual original reported results are retained with their endpoint boundaries. - Reason for missing information: Signals for other endpoints are verified. Original S01 results/plans for the selected response remain unverified. - Required materials and conditions: S01's complete agonist plans/results, dose-specific tables and presence/absence of the selected response. - Materials to obtain first: S01's complete agonist plans/results, dose-specific tables and presence/absence of the selected response. - Further research: Retain other-agonist signals; compare actual planning, measurement and results for the selected response against the original report. - Conditions for verification: Retain S01's partial collagen/epinephrine reductions and weak highest-dose ADP threshold under their original endpoints; do not transfer them to the selected response. - Why this condition is needed: Do not erase existing positive adjacent evidence merely to leave a gap. - Application exceptions: Do not substitute ADP threshold for reduced arachidonic acid maximum aggregation. - Remaining uncertainty: Signals for other endpoints are verified. Original S01 results/plans for the selected response remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01 ### N14 · Is the opposing 1995 result retained without transferring it to the selected response? Verification status: Met Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The 1995 garlic preparation concerns ADP, PAF and collagen aggregation and is retained as no significant in vivo oral effect. Arachidonic acid is not named in its retained endpoint, and matching to the AGE formulation remains unverified. - Why unverified: The opposing context is retained without becoming a direct selected-response null effect or effect of 0. - Reason for missing information: The original scope of the opposing report is verified. Measurement of the selected response in the entire paper and actual formulation identity remain unverified. - Required materials and conditions: Complete 1995 product/agonist methods, results and formulation specifications. - Materials to obtain first: Complete 1995 product/agonist methods, results and formulation specifications. - Further research: Compare the product and complete endpoint table; verify whether the selected response is direct and the original scope of the opposing result. - Conditions for verification: Retain the 1995 ADP/PAF/collagen result and unverified preparation identity; distinguish them from direct arachidonic acid refutation. - Why this condition is needed: Prevent both discarding an opposing result and transferring it to the wrong selected response. - Application exceptions: Do not treat nonsignificance as equivalence, AGE ineffectiveness or arachidonic acid ineffectiveness. - Remaining uncertainty: The original scope of the opposing report is verified. Measurement of the selected response in the entire paper and actual formulation identity remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S02 ### N15 · Are the broad 12-RCT review results and inclusion scope for the selected response verified? Verification status: Partly verified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The review reports 12 RCTs/595 people, 6 positive and the rest null, with heterogeneity preventing a firm conclusion. Included AGE arachidonic acid trials, results and denominators remain unverified in the current summary. - Why unverified: The overall review direction is known, but the eligible selected-response subset is unverified. - Reason for missing information: Overall review counts cannot verify selected-response trial numbers, participants or effects. - Required materials and conditions: Review included-trial tables, products/agonists, results/timing, denominators and overlap tables. - Materials to obtain first: Review included-trial tables, products/agonists, results/timing, denominators and overlap tables. - Further research: Separate the review by formulation and agonist; compare positive/no-difference results and directly eligible scope. - Conditions for verification: Retain the review's 12 RCTs, 595 people and 6 positive/rest null results; verify actual included AGE/arachidonic acid trials and results. - Why this condition is needed: Review direction and direct selected-response results are different facts. - Application exceptions: Do not turn 6 positive trials into 6 positive selected-response trials or count the review as separate clinical replication. - Remaining uncertainty: Overall review counts cannot verify selected-response trial numbers, participants or effects. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S03 ### N16 · Are the same 34 people, review included trials and selected-response families distinguished? Verification status: Partly verified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: S01's multiple doses/agonists belong to the same 34-person report context; S03 is a 12-RCT review. Overlap of S01/S02 with included review trials and the number of direct selected-response families remain unverified. - Why unverified: Report types and the shared trial context are known, but complete comparison of included-trial identity/overlap remains unresolved. - Reason for missing information: Unique selected-response trials/participants and overlap between the review and original reports remain unverified. - Required materials and conditions: A linkage table for registration/papers, recruitment/period, product, selected-response results and review included trials. - Materials to obtain first: A linkage table for registration/papers, recruitment/period, product, selected-response results and review included trials. - Further research: Create a report-trial-specimen/participant-endpoint linkage table; distinguish multiple reports and included trials. - Conditions for verification: Verify the same 34 people across original doses/endpoints and overlap from review recitation/included trials; leave the selected-response unique-family count unresolved. - Why this condition is needed: Do not count the same participants as independent populations for different endpoints. - Application exceptions: Do not assume that an arachidonic acid selected-response family exists or automatically generate unique counts. - Remaining uncertainty: Unique selected-response trials/participants and overlap between the review and original reports remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N17 · Is independent direct AGE arachidonic acid replication verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: With direct selected-response results unverified, independent AGE arachidonic acid replication is also unverified. Positive/opposing other-agonist results or a review are not selected-response replication results. - Why unverified: Independent replication cannot be certified without direct identity and results. - Reason for missing information: Directly eligible families and the distribution of replication results for the selected response remain unverified. - Required materials and conditions: Identity, product, population, comparison, results/timing and family tables for unique direct selected-response trials. - Materials to obtain first: Identity, product, population, comparison, results/timing and family tables for unique direct selected-response trials. - Further research: After verifying directly eligible conditions, compare independent-family results and differences in conditions. - Conditions for verification: Verify unique independent results under matching selected-response formulation, population, comparison, measure and timing conditions. - Why this condition is needed: Do not inherit original R0/I1 as an individual selected-response replication verdict. - Application exceptions: Unverified does not establish 0 studies worldwide or absence of effect. - Remaining uncertainty: Directly eligible families and the distribution of replication results for the selected response remain unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N18 · Are original funding clues and selected-response product/author independence verified? Verification status: Partly verified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Original funding values for all reports are retained. S01 product-support details and S02 funding are unverified; S03 has academic/mixed original-trial funding. Without direct selected-response report identity, product/author/COI information is also unverified. - Why unverified: Overall report funding clues exist, while selected-response independence remains unresolved. - Reason for missing information: Direct selected-response funding, product provision, author/institution/patent, declared COI and included-trial relationships are unavailable. - Required materials and conditions: Funding/COI, product support and author/institution information for original reports and included trials. - Materials to obtain first: Funding/COI, product support and author/institution information for original reports and included trials. - Further research: Identify an eligible selected-response report before separately comparing funding, product and author relationships. - Conditions for verification: Retain S01 unverified product-support details, S02 unverified funding and S03 academic/mixed funding; verify selected-response funding/product/author/COI. - Why this condition is needed: Unverified funding establishes neither independent funding nor absence of bias. - Application exceptions: Do not use the generic English funding field as actual verification of selected-response interests. - Remaining uncertainty: Direct selected-response funding, product provision, author/institution/patent, declared COI and included-trial relationships are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N19 · Are bleeding, event collection, denominators and follow-up for selected-response exposure verified? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The original broad statement that clinical thrombosis or bleeding was not measured is retained. Selected-response exposure identity, bleeding event/person counts, collection, duration, comparison, discontinuation and denominators remain unverified. - Why unverified: An experimental endpoint name and broad warnings do not provide selected-response safety tallies. - Reason for missing information: Harm definitions/collection, denominators, time, comparison and discontinuation information for matching selected-response exposure are unavailable. - Required materials and conditions: A product-matched safety population, AE definitions/collection, event/person counts, exposure/follow-up and discontinuation/comparison. - Materials to obtain first: A product-matched safety population, AE definitions/collection, event/person counts, exposure/follow-up and discontinuation/comparison. - Further research: Link selected-response exposure to actual safety populations/events; distinguish aggregation-test results from risk values. - Conditions for verification: Distinguish the aggregation-test gap from actual bleeding/severity/discontinuation definitions, comparisons, event/person counts, exposure/follow-up and collection. - Why this condition is needed: Do not convert unverified harms into no harm. - Application exceptions: Do not turn an unrecorded selected-response result into 0 events or substitute 34/595 as harm denominators. - Remaining uncertainty: Harm definitions/collection, denominators, time, comparison and discontinuation information for matching selected-response exposure are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N20 · Are original bleeding warnings and direct co-use/vulnerable-group data verified? Verification status: Partly verified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Warnings advise against unsupervised use with anticoagulants/antiplatelet medicines, bleeding disorders and around surgery. Direct selected-response exposure, events, follow-up and interaction magnitudes in those groups remain unverified. - Why unverified: Warning groups and scope are known, while actual vulnerable-group/co-use information remains unresolved. - Reason for missing information: Exposure, events, alternative causes/adjustment and long-term/rare-harm data for these co-use/vulnerable groups are unavailable. - Required materials and conditions: Products, exposure, events, follow-up, alternative explanations and original warning sources by co-use/group. - Materials to obtain first: Products, exposure, events, follow-up, alternative explanations and original warning sources by co-use/group. - Further research: Compare original warning support and actual group-specific safety data separately; do not certify personal safety. - Conditions for verification: Retain original anticoagulant/antiplatelet, bleeding-disorder and surgical warnings; verify direct selected-response exposure, events/alternatives and long-term/rare-harm information. - Why this condition is needed: Retain warnings separately from the efficacy gap. - Application exceptions: Retaining an original warning creates no new harm-causality verdict, safety grade or dosing prescription. - Remaining uncertainty: Exposure, events, alternative causes/adjustment and long-term/rare-harm data for these co-use/vulnerable groups are unavailable. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N21 · Does the named response also answer thrombosis-prevention or treatment-replacement questions? Verification status: Not applicable Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The selected question concerns a gap in direct evidence for arachidonic acid-induced responses. It makes no claim about clinical thrombosis prevention, thrombolysis, aspirin replacement or bleeding safety. - Why unverified: Separate clinical-event/treatment-replacement claims are outside the current question; event trials are not imposed as mandatory. - Reason for missing information: This table does not verify a direct clinical-event effect. The selected-response result itself also remains unverified. - Required materials and conditions: Definitions, comparators, denominators, follow-up and clinical results for a separate event question. - Materials to obtain first: Definitions, comparators, denominators, follow-up and clinical results for a separate event question. - Further research: Frame clinical-event questions under separate conditions; examine designs/follow-up different from aggregation testing. - Conditions for verification: Distinguish the selected-response aggregation-test gap from separate questions of clinical thrombosis/bleeding, thrombolysis and aspirin replacement. - Why this condition is needed: An experimental response name alone does not establish clinical prevention. - Application exceptions: Not applicable does not mean no clinical events, no harm or an effect of 0. - Remaining uncertainty: This table does not verify a direct clinical-event effect. The selected-response result itself also remains unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N22 · Are optimal dose, long-term effects and subgroups needed for this gap question? Verification status: Not applicable Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: This question asks whether direct AGE arachidonic acid material is verified. It makes no new optimal-dose, post-discontinuation persistence or special-subgroup effect claim. - Why unverified: Distinguish identity/result gaps from separate extensions; do not automatically make extension studies mandatory. - Reason for missing information: Retain the existing selected-response gap without adding every extension study as a new deficiency. - Required materials and conditions: If an extension is requested, direct selected-response dose comparisons, discontinuation/long-term and prespecified subgroup data. - Materials to obtain first: If an extension is requested, direct selected-response dose comparisons, discontinuation/long-term and prespecified subgroup data. - Further research: After verifying direct selected-response conditions, separately review prespecified analyses and effect modification for each extension. - Conditions for verification: Distinguish direct selected-response result identity from separate dose, discontinuation/long-term and subgroup-effect questions. - Why this condition is needed: Do not repurpose another dose trial as selected-response optimization. - Application exceptions: Do not erase other favorable results because a direct selected-response result is unavailable. - Remaining uncertainty: Retain the existing selected-response gap without adding every extension study as a new deficiency. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N23 · Are local summaries of the reports distinguished from unread external material? Verification status: Met Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The complete retained summary and all reports were read. External PubMed/DOI gateways and paper full texts remain unattempted, unacquired and unread; no direct arachidonic acid material was newly acquired. - Why unverified: Actual local summary reading and unread external material are separated and linked to exact source locations/identity. - Reason for missing information: The summary-reading scope is verified. External material types, responses, abstracts/full texts and licenses are unverified. - Required materials and conditions: Actual material-specific access/acquisition/reading records, versions/locations and physical material. - Materials to obtain first: Actual material-specific access/acquisition/reading records, versions/locations and physical material. - Further research: In authorized later reading, record material, level and version separately; compare summaries against original results. - Conditions for verification: Distinguish 3 evidence entries/3 citations and actual Korean/English local reading from unattempted, unacquired and unread external PubMed/DOI/full texts. - Why this condition is needed: A link or summary does not establish acquisition of original selected-response material. - Application exceptions: Do not inherit a report's access history onto a DOI gateway or treat unattempted access as failed access. - Remaining uncertainty: The summary-reading scope is verified. External material types, responses, abstracts/full texts and licenses are unverified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N24 · Are original reference dates and corrections distinguished from individual access dates? Verification status: Met Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: The original reference date and correction date for generic English wording are retained historically. Material-specific access date, reading scope and location are absent and unrecorded; current local review time is recorded separately. - Why unverified: Event attribution and absent fields are retained without backdating historical access to the present. - Reason for missing information: Historical access dates/full-text levels of individual materials remain unverified. Only the distinction between dates is verified. - Required materials and conditions: Historical material-specific access/version records and complete versions before/after corrections. - Materials to obtain first: Historical material-specific access/version records and complete versions before/after corrections. - Further research: Separate reference-date, correction and actual-reading events; compare dates and material levels. - Conditions for verification: Retain the original review date 2026-09-08 and correction 2026-09-14; distinguish the actual current date from unrecorded individual access dates. - Why this condition is needed: A global review date is not an access date for each external material. - Application exceptions: Do not turn historical research descriptions into current reading of arachidonic acid full texts. - Remaining uncertainty: Historical access dates/full-text levels of individual materials remain unverified. Only the distinction between dates is verified. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N25 · Is the scope of a current complete literature check for the arachidonic acid gap available? Verification status: Unverified Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Unverified arachidonic acid results describe the current retained evidence/citation scope. No new search or exhaustive unpublished/correction/retraction check was performed. The original research account separately describes the contemporary 34-person trial, review and opposing trial. - Why unverified: Actual search/inclusion logs establishing completeness beyond current material are unavailable. - Reason for missing information: The scope of current selected-response material, unpublished work and corrections/retractions is unverified; absence of research is not established. - Required materials and conditions: Contemporaneous queries/dates, inclusion/exclusion, agonist/formulation candidates and unpublished/correction/retraction logs. - Materials to obtain first: Contemporaneous queries/dates, inclusion/exclusion, agonist/formulation candidates and unpublished/correction/retraction logs. - Further research: In a separately authorized update, reproduce search scope using the named response and product conditions; compare actual omissions. - Conditions for verification: Verify actual queries, dates, inclusion/exclusion, unpublished/correction logs and the scope of the complete current evidence check for AGE arachidonic acid. Separately state the current summary gap and that no new search was performed. - Why this condition is needed: Reading the complete current source differs from an exhaustive current clinical-literature check. - Application exceptions: Do not turn 0 new searches into 0 selected-response studies or established nonreporting across the entire paper. - Remaining uncertainty: The scope of current selected-response material, unpublished work and corrections/retractions is unverified; absence of research is not established. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ### N26 · Are the C46 parent history and individual arachidonic acid status distinguished? Verification status: Met Reading scope: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. - Current findings: Original C, 46, B/S/R0/I1/EX/B2/CX and Warning remain historical records of the broad parent verdict. The individual arachidonic acid grade and actual selected-response observations are unrecorded. Generic English sample-size/result fields are not selected-response values or successful reading. - Why unverified: All original typed values and derived boundaries are retained; no new effect or grade is created. - Reason for missing information: Original-value preservation is verified. Selected-response efficacy, method certification and independent clinical validation were not newly performed. - Required materials and conditions: The complete original summary, identity, boundaries/verdict/corrections and derived-grade policy. - Materials to obtain first: The complete original summary, identity, boundaries/verdict/corrections and derived-grade policy. - Further research: Compare complete preserved original/case values and change events to check that no new selected-response verdict has been created. - Conditions for verification: Retain original grade/score/axes/Warning, all evidence values, empty arrays and corrections; explicitly state that a separate selected-response grade is unrecorded. - Why this condition is needed: The broad parent grade does not verify a direct selected-response effect. - Application exceptions: Do not turn an unrecorded observation into a numeric 0 or null effect. - Remaining uncertainty: Original-value preservation is verified. Selected-response efficacy, method certification and independent clinical validation were not newly performed. - Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application. - Related sources: S01, S02, S03 ## Evidence and sources ### S01 The effects of aged garlic extract on platelet aggregation and adhesion in humans [PubMed](https://pubmed.ncbi.nlm.nih.gov/11238801/) Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. Findings recorded in the summary: 34 people; partial collagen/epinephrine reductions; a weak ADP threshold signal only at the highest dose. A direct result for the selected response is unverified in the current summary. Record level: Context from the retained summary; direct AGE/arachidonic acid observations, analysis denominators and numerical results remain unverified. Independent replication: S01 concerns other agonists in a shared 34-person AGE dose trial. S02 concerns ADP, PAF and collagen with unverified AGE identity; S03 is a review of 12 RCTs and 595 people. Unique direct arachidonic acid trials/participants and review overlap remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | External PubMed bibliographic/abstract gateway | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | External DOI/publisher gateway | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | Original paper full text; direct location/version unverified | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | Retained verdict summary | Retained verdict summary read | Retained copy acquired; summary read | Stored existing review summary read | Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | ### S02 Effect of a garlic preparation on in vitro platelet aggregation in healthy subjects [PubMed](https://pubmed.ncbi.nlm.nih.gov/8582091/) Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. Findings recorded in the summary: A small sample of healthy men; ADP, PAF and collagen; no significant in vivo oral effect. AGE product identity and selected-response-specific estimates/CI remain unverified. Record level: Context from the retained summary; direct AGE/arachidonic acid observations, analysis denominators and numerical results remain unverified. Independent replication: S01 concerns other agonists in a shared 34-person AGE dose trial. S02 concerns ADP, PAF and collagen with unverified AGE identity; S03 is a review of 12 RCTs and 595 people. Unique direct arachidonic acid trials/participants and review overlap remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | External PubMed bibliographic/abstract gateway | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | External DOI/publisher gateway | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | Original paper full text; direct location/version unverified | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | Retained verdict summary | Retained verdict summary read | Retained copy acquired; summary read | Stored existing review summary read | Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | ### S03 Garlic supplementation and platelet aggregation: a systematic review of randomized controlled trials [PubMed](https://pubmed.ncbi.nlm.nih.gov/36222178/) Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted. Findings recorded in the summary: 12 RCTs and 595 people; 6 positive and the rest null; heterogeneity prevents a conclusion. Included trials, results and overlap for the selected response remain unverified. Record level: Context from the retained summary; direct AGE/arachidonic acid observations, analysis denominators and numerical results remain unverified. Independent replication: S01 concerns other agonists in a shared 34-person AGE dose trial. S02 concerns ADP, PAF and collagen with unverified AGE identity; S03 is a review of 12 RCTs and 595 people. Unique direct arachidonic acid trials/participants and review overlap remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | External PubMed bibliographic/abstract gateway | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | External DOI/publisher gateway | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | Original paper full text; direct location/version unverified | External access not attempted; not acquired; unread | External access not attempted; not acquired | Not read | The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | | Retained verdict summary | Retained verdict summary read | Retained copy acquired; summary read | Stored existing review summary read | Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion. | ## Review criteria and methods These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score. - M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Retained method-application records were reused. External originals were not reread and method content was not reassessed. - M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Retained method-application records were reused. External originals were not reread and method content was not reassessed. - M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Retained method-application records were reused. External originals were not reread and method content was not reassessed. - M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Retained method-application records were reused. External originals were not reread and method content was not reassessed. - M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Retained method-application records were reused. External originals were not reread and method content was not reassessed. ## What the statuses mean - Met: Limited verification of the retained identity, observation or scope required by this row. This is separate from clinical sufficiency or full-text certification. - Partly verified: Some facts needed by the question are known, while the stated analysis, population, formulation or denominator remains unverified. - Unverified: Direct information for this question is unverified in the retained scope. This does not mean an effect of 0, no studies, no harm or an unreviewed table. - Not applicable: A specific extension obligation lies outside the narrow question. This does not substitute for unread or unverified material. - Not applicable (alias): A grey-display alias of Not applicable. - Not read: The external material was not directly read in the current work. This is separate from reading the retained local summary. - Conflicting data: Actual disagreement between reports under the same conditions. Differences between other questions alone do not establish conflict. ## Change history 2026-10-26 · Public page/materials 1.0. The public view and materials were prepared from the existing 26 items. No new clinical search, verification-state change or scoring was performed.